-

Bruker Launches new timsMRMS Mass Spectrometry Platform for Unique Ultra-Complex Mixture Applications in the Energy Industry

SAN DIEGO--(BUSINESS WIRE)--At ASMS, Bruker Corporation (Nasdaq: BRKR) announced the launch of the new timsMRMS system, designed to empower researchers in petroleomics, sustainable fuels and advanced energy storage. The timsMRMS is an innovative platform that combines Trapped Ion Mobility Spectrometry (TIMS) with extreme-resolution Magnetic Resonance Mass Spectrometry (MRMS), to unravel the complex molecular makeup of challenging fossil fuels and green energy materials. It accomplishes this with unparalleled mass resolution (>10M) and sub-parts-per-million mass accuracy, plus isotope fine structure identification-confirmation, which enables the most confident identification of molecular species in ultra-complex mixtures.

As the global transition to more renewable energy accelerates, researchers face the challenge of analyzing ultra-high chemical complexity. The timsMRMS offers unprecedented capabilities for two vital areas in energy technology—renewable energy and energy storage.

  • Next-Gen Lithium Batteries: The timsMRMS enables ultra-high-confidence molecular characterization of electrolyte formulations, solid-electrolyte interphase (SEI) degradation, and molecular changes during charge-discharge cycles of lithium-ion batteries. This allows materials scientists to better understand and control the chemical mechanisms that dictate battery lifespan, safety, and energy density.
  • Advanced Bio-oils & Biofuels: By providing ultra-high-resolution clarity into molecular formulae determination and compound classes, the timsMRMS empowers researchers to address the chemical diversity of pyrolysis and biomass-derived oils, streamlining the development of sustainable, low-carbon transportation fuels.

“Many application areas in energy research present extreme levels of chemical diversity that are incredibly challenging. This has necessitated new analytical capabilities that go beyond traditional LC-MS limits,” said Dr. Paul Speir, Senior Vice President, Global MRMS Business with Bruker. “With the timsMRMS, we are equipping energy researchers with a complete unique tool that provides greater clarity and confidence in characterizing the extreme chemical complexity of next-generation batteries and alternative fuels.”

About Bruker Corporation – Leader of the Post-Genomic Era (Nasdaq: BRKR)

Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker’s high-performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in post-genomic life science molecular and cell biology research, in applied and biopharma applications, in microscopy and nanoanalysis, as well as in industrial and cleantech research, and next-gen semiconductor metrology in support of AI. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit www.bruker.com.

Contacts

Media Contact
Nora Williams
Bruker Daltonics Marketing Communications
T: +49 (421) 2205-2843
E: nora.williams@bruker.com

Investor Relations Contact
Joe Kostka
Director, Investor Relations
T: +1 (978) 313-5800
E: Investor.Relations@bruker.com

Bruker Corporation

NASDAQ:BRKR

Release Versions
$Cashtags
Hashtags

Contacts

Media Contact
Nora Williams
Bruker Daltonics Marketing Communications
T: +49 (421) 2205-2843
E: nora.williams@bruker.com

Investor Relations Contact
Joe Kostka
Director, Investor Relations
T: +1 (978) 313-5800
E: Investor.Relations@bruker.com

Social Media Profiles
More News From Bruker Corporation

Bruker Announces Strategic Collaboration with Atinary Technologies to Advance Self-Driving Laboratories

BOSTON--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR) today announced an expanded strategic collaboration with Atinary Technologies Inc., the pioneer of Self-Driving Labs® technologies and AI-driven R&D with applications in pharmaceuticals, chemicals, energy, and materials. Bruker also made a minority investment in Atinary. Financial details were not disclosed. Atinary intends to integrate Chemspeed configurable laboratory automation platforms, Bruker analytical instruments and SciY sc...

Bruker Announces Majority Investment in MIMETAS to Advance Human Physiology-Relevant Drug Discovery and Development

LEIDEN, The Netherlands--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR) today announced a majority investment in MIMETAS B.V., a developer of organ-on-a-chip platforms and advanced human tissue and disease models for drug discovery and development. The investment expands Bruker’s post-genomic solutions for disease biology research, as well as for drug discovery and development into Microphysiological Systems (MPS), also referred to as New Approach Methodologies (NAMs), and based on human ph...

Bruker Reports Second Quarter 2026 Financial Results

BILLERICA, Mass.--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR) today announced financial results for the three and six months ended June 30, 2026. Frank H. Laukien, Bruker’s President and CEO, commented: “We returned to organic revenue growth in the second quarter and our Scientific Instruments segment achieved 10% organic bookings growth year-over-year. Our focus on cost and profitability resulted in solid margin expansion and non-GAAP EPS growth in the quarter. In particular, we achieve...
Back to Newsroom